SecBot SecBot
8-K ·Filed Jun 3, 2026

CABA

Cabaletta Bio, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001759138-26-000030
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The data strongly de-risks the myositis registrational program and adds a second pivotal indication in SSc, expanding the addressable market. The PC-free lupus data, while early, supports a potential market expansion thesis. Key catalysts to watch: SSc registrational study initiation in 4Q26, topline DM/ASyS registrational data in mid-2027, and PC-free dose-ranging data across indications. The favorable safety profile supporting outpatient administration could improve commercial adoption if approved.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.58
T+0 close · Jun 3, 2026 · via day close
Latest settled
−5.59%
T+60 · $3.38
Vs SPY
−8.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $3.58entry
  2. T+1 · 6mo ago −1.96%α −2.35% · $3.51
  3. T+5 · 5mo ago −15.08%α −11.26% · $3.04
  4. T+20 · 5mo ago −10.89%α −9.89% · $3.19
  5. T+60 · 3mo ago −5.59%α −8.09% · $3.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 2026, including 83% (5/6) of dermatomyositis patients meeting the registrational primary endpoint, encouraging early PC-free lupus data showing deep B cell depletion in 1 of 2 patients, and plans to initiate a systemic sclerosis registrational study in 4Q26. The company also announced a 2H27 BLA submission target for myositis including adult and pediatric data, with potential for a priority review voucher.

Key Facts

  • 83% (5/6) of Phase 1/2 dermatomyositis patients achieved IM-free moderate-to-major TIS response at 16 weeks, meeting the registrational primary endpoint threshold
  • All 5 DM responders maintained IM-free response through latest follow-up as long as 1.5 years
  • First JDM patient achieved IM-free moderate TIS response at 16 weeks, maintained at 32 weeks; JDM to be included in 2H27 BLA submission
  • Systemic sclerosis announced as second pivotal indication; single-arm registrational study of ~25 patients with ILD expected to start in 4Q26
  • Lowest dose of PC-free rese-cel achieved deep B cell depletion in 1 of 2 lupus patients; second patient had ~90% B cell reduction
  • 94% of first 63 patients with preconditioning had no CRS or Grade 1 CRS only; 97% had no ICANS
  • BLA submission for adult DM and JDM planned for 2H27, potentially qualifying for a priority review voucher
  • SSc patients with ILD showed median 7.5% improvement in FVC at 36 weeks off immunomodulators

Financial Impact

No financial data provided in filing; company is pre-revenue clinical-stage biotech with $572M market cap

Risk Factors

  • Phase 1/2 data may not predict registrational trial outcomes; ASyS durability was variable
  • PC-free data is very early (2 lupus patients); higher dose cohorts still enrolling
  • BLA submission in 2H27 is over a year away; regulatory pathway and approval are uncertain
  • Company is pre-revenue with no approved products; will require additional capital to fund registrational trials and commercialization
  • Competition from other CD19-CAR T programs in autoimmunity and approved therapies (IVIg, brepocitinib, Vyvgart)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759138-26-000030
Document: caba-20260603.htm0001759138-26-000030
Document: caba-ex99_1.htm0001759138-26-000030
Document: 0001759138-26-000030-index-headers.html0001759138-26-000030
Document: 0001759138-26-000030-index.html0001759138-26-000030
Document: 0001759138-26-000030.txt0001759138-26-000030

Track record

29 reports on CABA

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026